About Neditol 2018-05-10T12:58:36+00:00





Welcome to neditol.co.uk

Neditol® XL is a prolonged-release capsule of tolterodine tartrate indicated in symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.1

Available as:

  • 4mg prolonged-release capsules
  • 2mg prolonged-release capsules (available for the first time in the UK)

Neditol XL is bioequivalent to Detrusitol® XL (Pfizer Limited, Surrey, UK).2

Neditol XL offers significant savings to your practice and clinical commissioning group (CCG).

Typically generic products are listed in category M of the UK Drug Tariff. On patent expiry of the originator product, the market price then declines significantly and savings are eventually passed on to the practice or CCG.

However, category C Drug Tariff products are often more difficult to manufacture and their reimbursed price remains the same whether it be an originator product or generic. Tolterodine 4mg prolonged-release capsules are in category C of the Drug Tariff.3

Neditol XL is different as Aspire Pharma have priced the product with the Department of Health to give your practice or CCG savings of up to 50% on the cost of the Category C Drug Tariff price for tolterodine 4mg prolonged-release capsules when Neditol XL is prescribed by brand.3*

At CCG level, the average cost of tolterodine XL prescribing is >£160,000. A change to Neditol XL would result in prescribing savings >£80,100.4**

In addition to making 50% cost savings,* Neditol XL:
• Available from mainline wholesalers;
• High level of stockholdings;
• Price guaranteed till 2019;***
• Bioequivalent to the originator brand;2
• Additional 2mg strength.

References: *50% saving on the cost of Category C tolterodine 4mg prolonged-release tablets in the UK Drug Tariff. **Based on the data in reference 4 for 211 CCGs switching their tolterodine prolonged-release tablets prescriptions to Neditol XL. ***No change in price subject to no material change to the products or Category C of the UK Drug Tariff until the 2019 PPRS review, regardless of competitor activity.
References 1) Neditol XL SmPCs. 2) Data on file. 1010067149 v 1.0 June 2016. 3) February 2017 UK Drug Tariff. 4) IMS Health BPI Data September 2013 – August 2014.

For further information please call: 01730 231148, email: info@aspirepharma.co.uk or visit www.aspirepharma.co.uk

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148
For more information about Neditol XL, please see the abbreviated prescribing information.
Revision reference – Neditol XL_16__27/02/2017